XML 36 R24.htm IDEA: XBRL DOCUMENT v3.25.3
Balance Sheet Information (Tables)
 9 Months Ended
Sep. 30, 2025
Balance Sheet Related Disclosures [Abstract]  
Schedule of of Cash and Cash Equivalents and Restricted Cash
A summary of cash and cash equivalents and restricted cash is as follows:
September 30, 2025December 31, 2024
Cash and Cash Equivalents$5,508,899 $3,792,322 
Restricted Cash, Non-current4,520 4,057 
Total Cash, Cash Equivalents and Restricted Cash$5,513,419 $3,796,379 
Schedule of Restricted Cash
A summary of cash and cash equivalents and restricted cash is as follows:
September 30, 2025December 31, 2024
Cash and Cash Equivalents$5,508,899 $3,792,322 
Restricted Cash, Non-current4,520 4,057 
Total Cash, Cash Equivalents and Restricted Cash$5,513,419 $3,796,379 
Schedule of Short term Investments
The following table summarizes short-term investments as of September 30, 2025 and December 31, 2024:
As of September 30, 2025
Unrealized
Amortized Cost
Gains
Losses
Estimated Fair Value
Government Agency Securities$10,202,625 $6,514 $— $10,209,139 
Corporate Debt Securities3,650,202 7,206 (1)3,657,407 
Total Short-term Investments$13,852,827 $13,720 $(1)$13,866,546 
As of December 31, 2024
Unrealized
Amortized Cost
Gains
Losses
Estimated Fair Value
US Treasuries$92,273 $40 $— $92,313 
Government Agency Securities18,517,164 28,008 (4,621)18,540,551 
Corporate Debt Securities4,058,879 5,901 (2,107)4,062,673 
Asset Backed Securities301,844 2,379 — 304,223 
Total Short-term Investments$22,970,160 $36,328 $(6,728)$22,999,760 
Debt Securities, Available-for-Sale
The following table summarizes the maturities of the Company's short-term investments at September 30, 2025 and December 31, 2024:
As of September 30, 2025
Amortized CostEstimated Fair Value
Due in one year or less$13,763,072 $13,776,261 
Due in one to five years89,755 90,285 
Total Short-term Investments$13,852,827 $13,866,546 
As of December 31, 2024
Amortized CostEstimated Fair Value
Due in one year or less$21,659,580 $21,688,074 
Due in one to five years1,310,580 1,311,686 
Total Short-term Investments$22,970,160 $22,999,760 
Schedule of Available-for-Sale Investments Gross Unrealized Losses and Fair Value
The following table shows the Company's available-for-sale investments' gross unrealized losses and fair value aggregated by investment category and length of time that individual securities have been in a continuous loss position, at September 30, 2025 and December 31, 2024:
As of September 30, 2025
Less than 12 months
CountFair ValueUnrealized Losses
Corporate Debt Securities1 $15,192 $(1)
Total1 $15,192 $(1)
As of December 31, 2024
Less than 12 months
CountFair ValueUnrealized Losses
Government Agency Securities4 $3,369,962 $(4,621)
Corporate Debt Securities9 801,149 (2,107)
Total13 $4,171,111 $(6,728)
Schedule of Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
September 30, 2025December 31, 2024
Prepaid Research and Development$444,742 $1,814,795 
Prepaid General and Administrative129,758 131,550 
Prepaid Insurance75,929 96,142 
Total Prepaid Expenses and Other Current Assets$650,429 $2,042,487 
Schedule of Tax and Other Receivables
Tax and other receivables consist of the following:
September 30, 2025December 31, 2024
Income Tax Receivables$1,025,000 $— 
Research and Development Tax Credit Receivables
401,664 223,184 
Other Tax Receivables28,092 47,063 
Total Tax Receivables$1,454,756 $270,246 
Schedule of Accrued Expenses
Accrued expenses consist of the following:
September 30, 2025December 31, 2024
Payroll and Benefits$1,178,548 $1,169,618 
Clinical Trials846,903 875,072 
Professional Fees58,749 55,032 
Income Tax— 2,328,042 
Other69,706 160,893 
Total Accrued Expenses$2,153,906 $4,588,657